283 related articles for article (PubMed ID: 17367763)
1. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
Roskoski R
Biochem Biophys Res Commun; 2007 May; 356(2):323-8. PubMed ID: 17367763
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
3. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
4. The potential role of sunitinib in gastrointestinal cancers other than GIST.
Grávalos C; Grande E; Gasent JM
Crit Rev Oncol Hematol; 2010 Oct; 76(1):36-43. PubMed ID: 20133148
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
6. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.
Catena R; Luis-Ravelo D; Antón I; Zandueta C; Salazar-Colocho P; Larzábal L; Calvo A; Lecanda F
Cancer Res; 2011 Jan; 71(1):164-74. PubMed ID: 21097719
[TBL] [Abstract][Full Text] [Related]
7. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
10. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Mar; 129():65-83. PubMed ID: 29408302
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
13. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
15. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Mena AC; Pulido EG; Guillén-Ponce C
Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab, sunitinib: osteonecrosis of the jaw.
Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
[No Abstract] [Full Text] [Related]
17. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
Andrae N; Kirches E; Hartig R; Haase D; Keilhoff G; Kalinski T; Mawrin C
Eur J Cancer; 2012 Aug; 48(12):1831-41. PubMed ID: 22391574
[TBL] [Abstract][Full Text] [Related]
18. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis for sunitinib efficacy and future clinical development.
Faivre S; Demetri G; Sargent W; Raymond E
Nat Rev Drug Discov; 2007 Sep; 6(9):734-45. PubMed ID: 17690708
[TBL] [Abstract][Full Text] [Related]
20. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
Bergers G; Song S; Meyer-Morse N; Bergsland E; Hanahan D
J Clin Invest; 2003 May; 111(9):1287-95. PubMed ID: 12727920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]